Disease · MONDO_0019933
Comparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 26
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Up-titrated to Pasireotide LAR 60 mg vs Pasireotide LAR Overall: deaths from any cause | 0 of 92 | 0 of 123 | 215 | NCT02354508 | Trial comparisons |
| Up-titrated to Pasireotide LAR 60 mg vs Pasireotide LAR Overall: serious adverse events | 6 of 92 | 12 of 123 | 215 | NCT02354508 | Trial comparisons |
| Lanreotide Autogel vs Lanreotide PR: deaths from any cause | 0 of 64 | 0 of 64 | 128 | NCT02493517 | Trial comparisons |
| Lanreotide Autogel vs Lanreotide PR: serious adverse events | 1 of 64 | 2 of 64 | 128 | NCT02493517 | Trial comparisons |
| Run-in Period vs Co-administration Period: deaths from any cause | 0 of 57 | 0 of 57 | 114 | NCT00383708 | Trial comparisons |
| Run-in Period vs Co-administration Period: serious adverse events | 2 of 57 | 8 of 57 | 114 | NCT00383708 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients With Clinical and Biochemical Control at the End of the RCT Phase | 36 of 55 | 27 of 37 | 92 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase | 50 of 55 | 37 of 37 | 92 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Analysis | 49 of 55 | 35 of 37 | 92 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients Who Maintain or Reduce the Overall Number of Active Acromegaly Symptoms at the End of the RCT Phase | 41 of 55 | 26 of 37 | 92 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients Who Maintain or Improve Their Overall Acromegaly Index of Severity (AIS) Score at the End of the RCT Phase | 40 of 55 | 25 of 37 | 92 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients Reporting Injection Site Reactions in the Acro-TSQ During the RCT Phase | 0 of 55 | 17 of 36 | 91 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients of Those Completing the RCT Phase Who Entered the Study Extension Phase | 34 of 54 | 18 of 35 | 89 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Week 26 Responders on Octreotide Capsules Who Are Biochemically Controlled at the End of the RCT Phase- Landmark Sensitivity Analysis | 45 of 48 | 34 of 36 | 84 | NCT02685709 | Trial comparisons |
| RCT Phase - Oral vs RCT Phase - Injectables: Proportion of Patients Reporting Interference With Daily Activities in Acro-TSQ During the RCT Phase | 0 of 55 | 13 of 16 | 71 | NCT02685709 | Trial comparisons |
| Paltusotine vs Placebo: deaths from any cause | 0 of 30 | 0 of 28 | 58 | NCT04837040 | Trial comparisons |
| Paltusotine vs Placebo: serious adverse events | 0 of 30 | 1 of 28 | 58 | NCT04837040 | Trial comparisons |
| Octreotide Capsules vs Placebo: Number of Patients Who Begin Rescue Treatment | 7 of 28 | 19 of 28 | 56 | NCT03252353 | Trial comparisons |
| Octreotide Capsules vs Placebo: Number of Patients Who Maintain Growth Hormone (GH) Response at the End of the Double Blind Placebo Controlled Period | 21 of 28 | 7 of 28 | 56 | NCT03252353 | Trial comparisons |
| Octreotide Capsules vs Matching Placebo: Number of Patients Who Maintain Their Biochemical Response at the End of the Double Blind Placebo Controlled (DPC) Period. | 16 of 28 | 5 of 28 | 56 | NCT03252353 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019933/comparisons